Prophylactic HPV vaccination provides an opportunity to profoundly affect 
cervical cancer incidence worldwide. The quadrivalent HPV VLP 6, 11, 16, 18 
vaccine (Gardasil) and the bivalent HPV VLP 16, 18 vaccine (Cervarix) are 
effective for prevention of HPV infection and cervical precancerous lesions. The 
quadrivalent vaccine is also effective for prevention of vulvar and vaginal 
lesions and genital warts. With the introduction of the vaccines general issues 
have to be raised such as optimal age for vaccination, duration of protection 
after vaccination, impact on cervical cancer screening, vaccination of males and 
feasibility of application to developing countries. The prospects of a vaccine 
which will protect against the most common viral sexually transmitted infection 
and thereby, protect against the complications of HPV infection such as cervical 
cancer is extremely appealing. The success of HPV vaccination as a major public 
health prevention opportunity, however, will entirely depend on efficient 
infrastructures to deliver the vaccines and on the acceptance by individuals, 
parents and health care providers.